PRECLINICAL EVALUATION OF INCB160058 - A NOVEL AND POTENTIALLY DISEASE-MODIFYING THERAPY FOR JAK2V617F MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Hamza Celik, 419115

IMPACT OF GENETIC BACKGROUND ON THE FIBROTIC TRANSFORMATION IN MURINE MPN-MODELS

EHA Library, Yu-An Lin, 419098

REAL WORLD PRACTICE REVEALS SERUM TNFΑ AS THE EARLY PROGNOSTIC PREDICTOR FOR MYELOFIBROSIS WITH RUXOLITINIB TREATMENT

EHA Library, Xinjie Chen, 419099

RKER-050, A MODIFIED ACTIVIN RECEPTOR TYPE IIA LIGAND TRAP, RESCUED ANEMIA AND INCREASED MUSCLE MASS AND STRENGTH IN A MOUSE MODEL OF MYELOFIBROSIS

EHA Library, Blake Moses, 419100

MONOCYTES WITH HIGHER EXPRESSION OF CD38 ACCELERATE MYELOFIBROSIS IN MPN

EHA Library, yiru yan, 419101

COMPLEX ALTERNATIVE SPLICING AND RELATED NEOANTIGEN PATTERNS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jing Sun, 419102

IMMUNOPHENOTYPIC ANALYSIS OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS RECEIVING THERAPY WITH THE BET INHIBITOR PELABRESIB

EHA Library, Rosa Andres Ejarque, 419103

T-CELL PHENOTYPING SUPPORTS THE USE OF T-CELL ENGAGING ANTIBODIES FOR TREATMENT OF CALRETICULIN MUTATED MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Anna Kuchnio, 419104

CDK8/19 INHIBITION: A PROMISING THERAPEUTIC STRATEGY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Zachary Zaroogian, 419105

ALK2 AND JAK2 INHIBITION FOR IMPROVED TREATMENT OF ANEMIA IN MYELOFIBROSIS PATIENTS: PRECLINICAL PROFILE OF AN ALK2 INHIBITOR ZILURGISERTIB IN COMBINATION WITH RUXOLITINIB

EHA Library, Ricardo Macarron, 419106

AGE-DEPENDENT LINK BETWEEN ARTERIAL THROMBOSIS AND SECONDARY CANCER IN PH-NEG MPN: CASE-CONTROL STUDY INSIGHTS

EHA Library, Tiziano Barbui, 419123

DECIPHERING THE PREDICTORS OF DEATH IN POLYCYTHEMIA VERA: FOCUS ON THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND THE INCIDENCE OF ARTERIAL THROMBOSIS

EHA Library, Tiziano Barbui, 419122

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH OUTCOMES IN A REAL-WORLD POPULATION OF PATIENTS WITH MYELOFIBROSIS TREATED WITH FEDRATINIB

EHA Library, Francesco Passamonti, 419121

IMPACT OF TP53 MUTATION ALLELIC BURDEN ON OUTCOME OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: A STUDY FROM COMMAND CONSORTIUM.

EHA Library, Talha Badar, 419120

THROMBOSIS RATES FOR MPN PATIENTS BY ATTAINED AGE AND TIME SINCE DIAGNOSIS: A SWEDISH REGISTER-BASED MATCHED-COHORT STUDY

EHA Library, Nurgul Batyrbekova, 419119

UNVEILING THE EFFECTIVENESS AND PREDICTIVE FACTORS OF JAKTINIB TREATMENT IN MYELOFIBROSIS PATIENTS WITH ANEMIA

EHA Library, Huafeng Wang, 419118

PROGRESSION TO MYELOFIBROSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: AN ANALYSIS FROM THE PROSPECTIVE MOST STUDY

EHA Library, Ruben Mesa, 419117

CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniel Moreno-Andrés, 419116

ESTABLISHMENT OF A NOVEL PRECLINICAL MOUSE MODEL FOR ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Martina Konantz, 419097

MUTATIONAL LANDSCAPE OF PATIENTS ENROLLED IN THE LOW-PV TRIAL WITH ROPEGINTERFERON ALFA-2B

EHA Library, Paola Guglielmelli, 419114

DUPLICATION OF CHROMOSOME 9P INDUCES T CELL EXHAUSTION AND INCREASED CLONOGENICITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN JAK2-MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ruggiero Norfo, 419113

HUMANIZED IMMUNOCOMPETENT MOUSE MODEL FOR THE PRECLINICAL THERAPEUTIC EVALUATION OF T CELL ENGAGING BISPECIFIC ANTIBODIES TARGETING CALRETICULIN MUTANT MPN

EHA Library, Shengen Xiong, 419112

MIR-93 ATTENUATES CALR MUTANT-DRIVEN ONCOGENIC ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Chih-Cheng Chen*, 419111

EXPRESSION OF GERMLINE JAK2 R1063H REPRESENTS INCREASED RISK OF THROMBOSIS AND IMPAIRS NORMAL HEMATOPOIETIC DEVELOPMENT IN MICE

EHA Library, Veronika Zimolova, 419110

INFLAMMATION NOT HAEMATOPOIESIS CAUSES SPLENOMEGALY IN A MOUSE MODEL OF POLYCYTHAEMIA VERA.

EHA Library, Cavan Bennett, 419109

EFFECT OF NOVEL AGENTS ON THE MECHANISM OF FIBROCYTE-MEDIATED INDUCTION OF MYELOFIBROSIS

EHA Library, Takaaki Maekawa, 419108

FEDRATINIB INHIBITS IMMUNE EVASION AND RESTORES B CELL MATURATION: BIOMARKER ANALYSIS FROM THE FREEDOM2 STUDY

EHA Library, Claire Harrison, 419107

How to Make the Most out of a Rapidly Evolving Treatment Landscape: Bispecific Antibodies in Relapsed Refractory Multiple Myeloma (RRMM)

EHA Library, Pfizer, 4144087

T-cell engaging immunotherapy in early treatment of B-cell acute lymphoblastic leukemia (B-ALL)

EHA Library, Amgen, 4144088

RESULTS FROM THE RANDOMIZED PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS POMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN REPALPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 4136513

INTRA- AND EXTRACELLULAR PROTEOME DYNAMICS DURING NORMAL AND MALIGNANT HEMATOPOIETIC STEM CELL EXPANSION

EHA Library, Maria Jassinskaja, 4136514

ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED ECHO TRIAL

EHA Library, Michael L. Wang, 4136515

GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)

EHA Library, Jeremy Abramson, 4136516

ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2-MONTH SURVIVAL OF TREATMENT-NAIVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY

EHA Library, Abhishek Maiti, 4136517

ELEVATED HEMOGLOBIN OF ANDEAN AYMARAS IS CAUSED BY ALTERNATIVELY SPLICED NFKB1

EHA Library, Josef Prchal, 4136518

VITAMIN C SUPPLEMENTATION IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE OR LOW-RISK MYELOID MALIGNANCIES: RESULTS FROM EVI-2, A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 STUDY

EHA Library, Stine Ulrik Mikkelsen, 4136519

Abstract Book 2024

EHA Library, Faculty / Presenters, 422826

Education Sessions on Diffuse Large B-cell Lymphoma (DLBCL)

EHA Library, Faculty / Presenters, 402925

Education Session on Immunotherapy in indolent lymphomas

EHA Library, Faculty / Presenters, 402950

Education Session on Myelodysplastic syndromes (MDS)

EHA Library, Faculty / Presenters, 402946

Education Session on What's new in myeloproliferative neoplasms (MPN)?

EHA Library, Faculty / Presenters, 402945

Education Session on What is hot in hemophilia?

EHA Library, Faculty / Presenters, 402944

Education Session on Pediatric acute myeloid leukemia (AML)

EHA Library, Faculty / Presenters, 402937

Education Session on Fetal-neonatal cytopenias: Focus on anemia

EHA Library, Faculty / Presenters, 402926

Education Session on Genetics across all lymphoid malignancies

EHA Library, Faculty / Presenters, 402927

Education Session on Hematopoietic stem cell biology and transplantation

EHA Library, Faculty / Presenters, 402928

Education Session on Hemochromatosis: From novel classification to treatment guidelines

EHA Library, Faculty / Presenters, 402929

Education Session on Inherited red blood cell disorders

EHA Library, Faculty / Presenters, 402932

Education Session on Novel agents in multiple myeloma

EHA Library, Faculty / Presenters, 402933

Education Session on Novel therapeutic approaches in acute myeloid leukemia (AML)

EHA Library, Faculty / Presenters, 402936

Education Sessions on CNS-involvement in acute lymphoblastic leukemia (ALL)

EHA Library, Faculty / Presenters, 402769

Education Sessions on Chronic myeloid leukemia (CML)

EHA Library, Faculty / Presenters, 402755

Education Session on Chronic lymphocytic leukemia (CLL)

EHA Library, Faculty / Presenters, 402754

Education session on Acute chest syndrome in sickle cell disease

EHA Library, Faculty / Presenters, 402753

Presidential Session II

EHA Library, Faculty / Presenters, 402752

Presidential Session I & Awards

EHA Library, Faculty / Presenters, 402751

Education Session on Acute acquired thrombosis and hemostasis challenges

EHA Library, Faculty / Presenters, 402750

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT

EHA Library, Wojciech Jurczak, 385537

HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

EHA Library, Ryan Jacobs, 387924

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

EHA Library, Meletios Dimopoulos, 387899

INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Francesca Palandri, 385512

EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sagar Lonial, 387240

PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY

EHA Library, Francesco Passamonti, 387868

EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY

EHA Library, Francesco Passamonti, 387867

LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Matteo Giovanni Della, 387802

FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Johannes Duell, 387406

IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2

EHA Library, Ruben Mesa, 387290

SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL

EHA Library, Tycel Phillips, 385544

BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE

EHA Library, Michel Delforge, 387224

CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS

EHA Library, Guillermo Garcia-Manero, 387135

A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Guillermo Garcia-Manero, 387132

PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

EHA Library, Vania Hungria, 386793

FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY

EHA Library, Johannes Duell, 385588

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

EHA Library, Thierry Facon, 386745

A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA

EHA Library, Anthony Selwyn Stein, 386323

PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT):  IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

EHA Library, Michel Delforge, 386734

A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING

EHA Library, Keri Maher, 386344

CARDIOTOXICITY OF CPX-351 VS 7+3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA

EHA Library, Jorge Cortes, 386345

SURVIVAL OUTCOMES WITH CPX-351 VS 7+3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY

EHA Library, Jorge CORTES, 386346

PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Shaun Fleming, 386396

A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9

EHA Library, Saad Z Usmani, 386693

BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

EHA Library, Yi Lin, 386638

BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Marc S. Raab, 386630

TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES

EHA Library, Sudipto Mukherjee, 386562

LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Uwe Platzbecker, 386522

LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

EHA Library, Wojciech Jurczak, 386447

IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID-19 PANDEMIC

EHA Library, Bart Scott, 386418

RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME

EHA Library, Jean Donadieu, 387880

LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2

EHA Library, Jian‑Qing Mi, 386703

LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Surbhi Sidana, 386708

DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

EHA Library, Manisha Bhutani, 386710

ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1

EHA Library, Leo Rasche, 386721

EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1

EHA Library, Niels W C J van de Donk, 386740

PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP

EHA Library, Jay R. Hydren, 386761

PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Cyrille Touzeau, 387891

FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, María-Victoria Mateos, 387890

TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS

EHA Library, Nizar J Bahlis, 387892

CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

EHA Library, Nico Gagelmann, 385487

SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS

EHA Library, Jan Bewersdorf, 385480